Donnelly, Conor
Dykstra, Brad
Mondal, Nandini
Huang, Junning
Kaskow, Belinda J.
Griffin, Russell
Sackstein, Robert
Baecher-Allan, Clare
Article History
Received: 21 September 2017
Accepted: 4 December 2017
First Online: 11 January 2018
Competing Interests
: <b>(Robert Sackstein) (the only author to have such interests):</b> According to the National Institutes of Health policies and procedures, the Brigham & Women’s Hospital has assigned intellectual property rights regarding HCELL and glycosyltransferase-programmed stereo-substitution (GPS) to the inventor (R.S.), who may benefit financially if the technology is licensed. R.S.’s ownership interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policy. R.S. declares that he has Equity in Warrior Therapeutics LLC, IP ownership of GPS technology and HCELL, and serves as a consultant to Mesoblast LTD and to DaVinci Biosciences.